OptimizeRx (OPRX) Q3 2026: Beat on Both Lines, Guidance Cut Stings

OptimizeRx posted adjusted EPS of $0.20 against a consensus of $0.16, a beat of about 23%, while revenue of $21.6 million cleared the $21.2 million estimate by roughly 2%. Those are genuine positives, but they were immediately overshadowed by what management said about the rest of the year.

The company lowered its full-year 2026 revenue guidance to a range of $87 million to $93 million, down from the prior $95 million to $100 million range. Management cited limited visibility into fourth-quarter buy-ups and noted that 2026 contracted revenue is tracking about 20% below the prior year. That gap between beats and a sharp guidance cut is what sent shares lower after hours.

The margin story is the clearest bright spot in the report. Adjusted EBITDA margin expanded to roughly 29% in the quarter from about 20% a year earlier, a gain of around 900 basis points. Operating income rose 30% year over year and net income climbed 53%, gains driven by a favorable product mix and a cost-reduction initiative completed in the first half of 2026. Full-year adjusted EBITDA guidance was left unchanged at $21 million to $25 million, signaling that management believes profitability is durable even as the top line contracts.

The revenue decline itself, 17% year over year, was attributed to a small number of large customers pulling back spending, including clients that had used lower-margin direct-to-consumer managed services in the prior-year period, as well as broader pharmaceutical budget pressure tied to drug-pricing uncertainty. Net revenue retention fell to 83% from 121%, underscoring just how much of the pressure is coming from existing accounts spending less rather than from customer losses alone.

There are reasons to look beyond the guidance cut. CEO Stephen L. Silvestro disclosed that one previously displaced top-five client has returned and begun reinvesting, and that early 2027 contracted revenue is running about 20% ahead of the comparable prior-year point. The company also ended the quarter with $22.3 million in cash, up 14% year over year, and total liabilities have fallen 41% over the same period. Management plans to accelerate share repurchases in Q4 and continue paying down the remaining $10.4 million in debt ahead of schedule.